The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
Rising PSA (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).
Post radical prostatectomy (RP) - AUA recommendation for biochemical recurrence after radical prostatectomy
PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.
Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy
Nadir + greater than or equal to 2 ng/mL rise in PSA
Karnofsky performance status of > 50 (or ECOG/WHO equivalent).
Age > 18.
Ability to understand a written informed consent document, and the willingness to sign it.
You CAN'T join if...
Unable to lie flat, still or tolerate a PET scan.
Concomitant investigational therapy.
Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).
UCSF Imaging Center at China Basinaccepting new patients San Francisco, California, 94107, United States